Old West Investment Management LLC Takes $2.20 Million Position in Ralliant Corporation $RAL

Old West Investment Management LLC bought a new position in shares of Ralliant Corporation (NYSE:RAL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 29,903 shares of the company’s stock, valued at approximately $2,202,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Danske Bank A S acquired a new position in Ralliant during the 4th quarter valued at about $25,000. Allworth Financial LP lifted its holdings in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares in the last quarter. Palisade Asset Management LLC bought a new position in shares of Ralliant in the third quarter valued at approximately $26,000. BOKF NA bought a new position in shares of Ralliant in the third quarter valued at approximately $29,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Ralliant during the third quarter valued at approximately $30,000.

Analyst Ratings Changes

RAL has been the subject of a number of analyst reports. Barclays increased their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. BMO Capital Markets initiated coverage on shares of Ralliant in a research note on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price for the company. Wall Street Zen downgraded shares of Ralliant from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. Finally, Truist Financial restated a “buy” rating and set a $82.00 price target (up from $68.00) on shares of Ralliant in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $75.70.

Ralliant Stock Performance

Shares of RAL opened at $72.34 on Monday. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The company has a market capitalization of $8.00 billion, a price-to-earnings ratio of -6.67, a PEG ratio of 2.69 and a beta of 1.61. The stock has a 50 day moving average of $68.60 and a 200 day moving average of $55.45. Ralliant Corporation has a 12 month low of $37.27 and a 12 month high of $75.41.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, sell-side analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s payout ratio is presently -1.84%.

Ralliant Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.